SCHEDULE: Longitude Capital Discloses Veradermics Stake

Longitude Capital entities and individuals disclose a combined 9.8% beneficial ownership in Veradermics, Inc. following recent share sales.

Summary

• This filing is an amendment to a Schedule 13D, indicating changes in beneficial ownership of Veradermics, Inc. common stock.
• The reporting persons, including Longitude Capital Partners V, LLC, Longitude Venture Partners V, L.P., Longitude 103.8 East Partners, LLC, Longitude 103.8 East, L.P., Patrick G. Enright, and Juliet Tammenoms Bakker, collectively hold a significant stake.
• As of November 5, 2026, the total beneficial ownership reported is 4,153,873 shares, representing 9.8% of the outstanding common stock.
• This percentage is based on 42,195,472 shares of common stock outstanding, as reported by Veradermics, Inc. on November 10, 2026.
• On November 11, 2026, two transactions occurred: LVPV sold 250,000 shares at $150.38 per share, and L103 sold 250,000 shares at $150.38 per share.
• Patrick G. Enright is noted as a member of Veradermics, Inc.'s board of directors.
• The reporting persons expressly disclaim status as a group for the purposes of Section 13(d)(3) of the Exchange Act, despite an agreement to file jointly.
• They also disclaim beneficial ownership except to the extent of their pecuniary interest, other than shares held of record.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant ownership stake and recent transactions without immediate indications of aggressive action or negative developments.

Positives

• Significant beneficial ownership of 9.8% by Longitude Capital entities and associated individuals in Veradermics, Inc.
• Patrick G. Enright's position on the Issuer's board of directors suggests potential alignment and influence.
• Recent share sales indicate liquidity and active management of the investment portfolio.

Negatives

• The filing is an amendment, suggesting a change in the reporting persons' holdings or strategy.
• The disclaimer of group status, despite an agreement to file jointly, could indicate potential strategic divergence or a technicality to avoid certain regulatory implications.

Risks

• Potential for future changes in beneficial ownership, as this is an amendment to a Schedule 13D.
• The disclaimer of group status might lead to uncertainty regarding coordinated actions among the reporting persons.
• As a significant shareholder, Longitude Capital's investment decisions could impact Veradermics' stock price.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. It primarily reports on current beneficial ownership and recent transactions.

Management Comments

• Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person.
• The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.
• Patrick G. Enright, a member of the Issuer's board of directors, and Juliet Tammenoms Bakker are the managing members of each of LCPV and L103P and may each be deemed to share voting and dispositive power with respect to the shares held by LVPV and L103.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are common for institutional investors and significant stakeholders in the biotechnology and healthcare sectors, where Veradermics, Inc. likely operates. These filings signal changes in ownership and potential strategic interests.

Stakeholder Impact

• Shareholders may be influenced by the significant stake held by Longitude Capital and their potential strategic intentions.
• The board of directors of Veradermics, Inc. will be aware of the substantial ownership by Longitude Capital, including a board member from this group.

Next Steps

• Continued monitoring of Veradermics, Inc. filings for any further changes in beneficial ownership or strategic actions by Longitude Capital.
• Observation of any future board-level decisions or strategic shifts influenced by the significant stake held by the reporting persons.

Key Dates

Recommendation

The filing indicates a significant ownership stake and recent transactions, but without clear indications of a change in strategy or aggressive action. The presence of a board member from the reporting group suggests ongoing involvement, warranting a 'hold' to observe future developments.

Keywords

Schedule 13D, Beneficial Ownership, Longitude Capital, Veradermics, Common Stock, Amendment, Shareholder